Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 4 1Phase 3 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 7Thyroid Carcinoma, Anaplastic 3Thyroid Cancer, Papillary 3Neoplasms 3Multiple Endocrine Neoplasia Type 1 3Thyroid Neoplasms 2Somatostatinoma 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Multiple Myeloma 2Laryngeal Neoplasms 2Hematologic Neoplasms 2Glioma 2Gastroenteropancreatic Neuroendocrine Tumors 2Erdheim-Chester Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adrenal Gland Neoplasms 2Adenoma, Islet Cell 2Vipoma 1Thyroid cancer, Hurthle cell 1Pituitary Neoplasms 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Muscle Weakness 1Motor Activity 1Melanoma 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Hyperaldosteronism × Endocrine × Clear all
NCT06100367 2025-12-02

11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours

Changi General Hospital

Phase 2/3 Active not recruiting
100 enrolled
Endocrine

Adrenal Gland Neoplasms, Hyperaldosteronism, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡